FRIDAY, Feb. 7, 2014 (HealthDay News) -- A so-called implantable
insulin delivery device could one day free people with type 1
diabetes from the need for multiple daily injections, scientists
"Diabetes is a difficult-to-treat condition, and yet keeping in very good balance all the time is the only way to maintain good health," said the lead researcher on the project, Joan Taylor, a professor of pharmacy at De Montfort University in Leicester, England.
Taylor and her colleagues hope to have the device ready for
human trials in as soon as two years.
The device, which is currently dubbed "a self-regulating insulin
delivery device," would be implanted in the abdomen. The outside of
the device would be made of plastic or metal. There would be no
electronic or moving parts, according to Taylor. The device
wouldn't need batteries, and because it's not made of biological
material, there's no worry of rejection, she said.
The device would house a refillable insulin reservoir that would
contain insulin with a protective gel layer. The insulin and gel
would need to be replaced approximately every two weeks.
That gel layer would react to the presence of sugar (glucose) in
"The gel material contains a lock-and-key chemical interaction that holds the gel together and this is interrupted by the presence of glucose that enters the device gel layer from the fluid surrounding it in the body. When the gel softens, the insulin in it travels much more quickly and reaches the body circulation. Once the insulin has lowered the blood glucose, glucose starts to leave the gel again and the gel hardens, effectively closing the gateway," Taylor explained.
This type of insulin delivery more closely mimics the natural
delivery of insulin than does an insulin injection, Taylor said.
Insulin is a hormone that's necessary for the body to metabolize
the carbohydrates in food. Carbohydrates transform into glucose
during digestion to provide fuel for the body's cells. But, without
insulin, the glucose can't enter the cells and builds up in the
High blood sugar (glucose) levels can eventually lead to serious
complications, such as kidney or heart disease and vision problems.
But, low blood sugar levels can also be dangerous, even potentially
"If [the gel] did not re-harden, the dose released would be higher than it should be," said Taylor, who added that the research team is working to ensure that insulin won't gush out. Or perhaps the researchers could design the device with a way to disable the delivery of insulin if necessary, she said.
"It goes without saying that the medical engineering needs to be perfect. It must not leak or be vulnerable to easy damage. We absolutely recognize that insulin is an extremely potent drug that needs respect," Taylor said.
Sanjoy Dutta, senior director of treatment therapies at JDRF
(formerly known as the Juvenile Diabetes Research Foundation), said
he's intrigued by Taylor's research, but added that there are
"challenges for these researchers and other groups who are trying
to develop implanted devices and glucose responsive insulin."
The ideal glucose responsive insulin needs to "deliver the right
amount of insulin, which means you would not need to carb-count;
you would not need to worry about [the effect on your blood sugar
from] exercising one day and not the next; you would not have to
worry about how stress [might change your blood sugar]," Dutta
said. "Ideally, it should almost work like a pancreas, but this
will take a long time to develop."
However, Dutta noted that just 10 years ago people thought an
artificial pancreas was a distant dream, yet an early version of
such a system was approved by the U.S. Food and Drug Administration
last summer. The artificial pancreas is worn outside the body and
consists of a continuous glucose monitoring system, an insulin
pump, and software with a sophisticated algorithm to predict blood
There are several different types of artificial pancreas systems
currently in clinical trials. The goal is to have a closed-loop
system that would allow someone with diabetes to let the device
take over the management of their blood sugar levels. The system
already approved by the FDA is called a low-glucose suspend system,
and it shuts down insulin delivery when it senses that blood sugar
levels have dropped too low. This system still requires the person
with diabetes to direct most of their daily care, however.
Dutta said that "a true glucose responsive insulin will trump a
closed-loop artificial pancreas system any day, but the question is
how long will it take us to get to a true glucose responsive
Dutta and Taylor expect that both the implanted device under
development in Britain -- which is not an artificial pancreas --
and the insulin encased in a glucose responsive gel will face a
number of regulatory hurdles worldwide.
"The FDA will look at this with a fine-tooth comb. They will require many studies and safety data," said Dutta. But, he added, approval is not impossible. Other products that combine medications with medical devices, such as drug-eluting cardiac stents, have already been approved, he noted.
Learn more about type 1 diabetes from the
U.S. National Library of Medicine.
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.